Wells Fargo resumed coverage on Alaunos Therapeutics with a new price target

10/4/22 7:18:05 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Wells Fargo resumed coverage of Alaunos Therapeutics with a rating of Overweight and set a new price target of $3.00

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$TCRT

Date	Price Target	Rating	Analyst
10/4/2022	$3.00	Overweight	Wells Fargo